Salem Radio Network News Saturday, January 22, 2022


India’s Serum Institute resumes vaccine exports under COVAX facility

BENGALURU (Reuters) -Serum Institute of India (SII), the world’s biggest vaccine maker, said on Friday it shipped the first batch of AstraZeneca’s COVID-19 vaccine, branded as Covishield, to the COVAX vaccine-sharing programme after an eight-month hiatus.

India in March put a temporary hold on all major exports of the AstraZeneca coronavirus shot made by the family-run firm in order to inoculate its own citizens as the country struggled to manage a devastating surge of COVID-19 cases.

The resumption of exports was linked to SII surpassing its original target to produce 1 billion doses of Covishield by the end of the year, the company said, adding that the total number of vaccine doses produced have crossed 1.25 billion.

SII said its supply of doses via COVAX was expected to increase substantially into the first quarter of 2022.

To boost its COVID-19 vaccine output further, SII will bring into production other vaccines under licence, including COVOVAX, from U.S.-based Novavax.

(Reporting by Shivani Singh and Chris Thomas in Bengaluru; Editing by Shounak Dasgupta)


Editorial Cartoons

View More »

Michael Ramirez
Tue, Jan 11, 2022